title: Sirolimus for below the knee lesions: mid-term results of SiroBTK study.
abstract: OBJECTIVE
  To assess the safety and efficacy of sirolimus-eluting stents (SESs) in the treatment of severe intermittent claudication and critical limb ischaemia with "below-the-knee" lesions, unsuitable for surgery.
  
  
  BACKGROUND
  Limited published evidence suggests that drug-eluting stents may offer significant improvements in the treatment of infrapopliteal lesions.
  
  
  METHODS
  Thirty consecutive patients with either severe intermittent claudication or critical limb ischemia (CLI), category 3-6 of Rutherford classification, and multivessel disease of infrapopliteal arteries (> or = 2 vessels) were treated with SES. Sixty-two arteries were treated with 106 SES. Mean age was 73.9 years, 77% of patients were male and 36% diabetic. The primary endpoint was clinical improvement and healing of ulcers at short term (1 month) and mid term (7.7 months). The secondary endpoint was primary vessel patency rate (angiographic or duplex assessment). All patients received clopidogrel (75 mg daily) or ticlopidine (150 mg daily) for 2 months or longer.
  
  
  RESULTS
  Angiographic and procedural success was achieved in all patients. At 7 months (7.7 +/- 5.8), it was necessary to amputate 1 toe in one patient and 1 mid-foot in another. Limb salvage was obtained in 100% of patients. Other events were: two cardiac deaths unrelated to CLI, one stroke with hemiparesia, one initial reperfusion syndrome, one contralateral CLI, and three recurrent homolateral claudication cases. All surviving patients had a mid-term clinical improvement with 97% of primary patency (56 patent arteries on 58 arteries).
  
  
  CONCLUSIONS
  Treatment of "below-the-knee" lesions with SES may provide an alternative treatment for patients with CLI.
authors.affiliation: Département de Cardiologie et Radiologie Vasculaire Interventionelles, Polyclinique Les Fleurs, 83190 Ollioules, France. p.commeau@wanadoo.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Commeau
authors.forename: Paul
authors.initials: P
authors.lastname: Barragan
authors.forename: Pierre O
authors.initials: PO
authors.lastname: Roquebert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019917:Blood Vessel Prosthesis Implantation; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use; D004869:Equipment Safety; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D053208:Kaplan-Meier Estimate; D007866:Leg / Q000098:blood supply* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011150:Popliteal Artery / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D011446:Prospective Studies; D012107:Research Design; D012720:Severity of Illness Index; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus